Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin

[1]  Eshel Ben-Jacob,et al.  Towards elucidating the connection between epithelial–mesenchymal transitions and stemness , 2014, Journal of The Royal Society Interface.

[2]  E. Asselin,et al.  Resveratrol Inhibits Cisplatin-Induced Epithelial-to-Mesenchymal Transition in Ovarian Cancer Cell Lines , 2014, PloS one.

[3]  G. Crepaldi,et al.  Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old , 2014, Cancer Chemotherapy and Pharmacology.

[4]  Eshel Ben-Jacob,et al.  MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination , 2013, Proceedings of the National Academy of Sciences.

[5]  H. Cao,et al.  Penton-Dodecahedral Particles Trigger Opening of Intercellular Junctions and Facilitate Viral Spread during Adenovirus Serotype 3 Infection of Epithelial Cells , 2013, PLoS pathogens.

[6]  J. Gralow,et al.  Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2 , 2013, Journal of Virology.

[7]  C. Yun,et al.  Strategies to Increase Drug Penetration in Solid Tumors , 2013, Front. Oncol..

[8]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[9]  K. Partanen,et al.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Carter,et al.  Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs , 2012, Clinical Cancer Research.

[11]  Raymond D. Harris,et al.  A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer , 2012, Clinical Cancer Research.

[12]  H. Cao,et al.  A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses , 2012, Journal of Virology.

[13]  Jiri Bartek,et al.  Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. , 2011, Cancer research.

[14]  M. Quinn,et al.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.

[15]  Hongjie Wang,et al.  Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions , 2011, Journal of Virology.

[16]  Jiri Bartek,et al.  Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PloS one.

[17]  J. Brunet,et al.  Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells , 2011, Journal of cellular biochemistry.

[18]  T. Möller,et al.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14 , 2010, Nature Medicine.

[19]  K. Partanen,et al.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  T. Cheng,et al.  Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. , 2010, Bioconjugate chemistry.

[21]  Ian F Tannock,et al.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors , 2010, BMC Cancer.

[22]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[23]  A. Ristimäki,et al.  Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors , 2010, Gene Therapy.

[24]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[25]  Christian Morawe,et al.  The ID23-2 structural biology microfocus beamline at the ESRF , 2009, Journal of synchrotron radiation.

[26]  Olof Svensson,et al.  EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis. , 2009, Journal of synchrotron radiation.

[27]  T. Möller,et al.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. , 2009, Cancer research.

[28]  C. Bamdad,et al.  MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells , 2009, Breast Cancer Research and Treatment.

[29]  D. Radisky,et al.  Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression? , 2008, Nature Clinical Practice Oncology.

[30]  C. Verlinde,et al.  Identification of CD46 Binding Sites within the Adenovirus Serotype 35 Fiber Knob , 2007, Journal of Virology.

[31]  Todd J. McWhorter,et al.  Mechanistic bases for differences in passive absorption , 2007, Journal of Experimental Biology.

[32]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[33]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[34]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[35]  H. Höfler,et al.  Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer , 2005, The Journal of pathology.

[36]  R. Kerbel,et al.  Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. , 2002, Cancer research.

[37]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  S. Cusack,et al.  Structure of the fiber head of Ad3, a non-CAR-binding serotype of adenovirus. , 2001, Virology.

[39]  I. Walker,et al.  Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2‐year review , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  J. Hainsworth,et al.  Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Markman,et al.  Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. , 2000, Gynecologic oncology.

[42]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Iwatsuki,et al.  Abnormal desmoglein expression by squamous cell carcinoma cells. , 1996, Acta dermato-venereologica.

[44]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[45]  Sangamo BioSciences Announces Presentations On ZFP Therapeutic ® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy , 2022 .